Financial
FY2025 revenue $44.56bn (+3.9%); operating margin 17.4%; net income $6.70bn.
Cash $9.85bn; debt $39.38bn.
Thermo Fisher Scientific
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: TMO
FY2025 revenue $44.56bn (+3.9%); operating margin 17.4%; net income $6.70bn.
Cash $9.85bn; debt $39.38bn.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$44.6bn | +3.9% | US$7.7bn | US$6.7bn | Thermo Fisher Scientific |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Not yet researched.
Cyber & information governance
Not yet researched.
Regulatory & clinical safety
Not yet researched.
Contract performance
Not yet researched.
Competitors
No competitors linked yet.